AstraZeneca says Ultomiris meets primary endpoint in phase III trial

(Alliance News) - AstraZeneca PLC on Tuesday reported positive findings from trial results studying its kidney disease treatment, Ultomiris.

The Cambridge, England-based pharmaceuticals company said the I CAN phase III trial showed that Ultomiris met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in excess protein in urine of adults with a chronic autoimmune kidney disease.

The safety profile observed in the trial was consistent with the known profile of Ultomiris, with no new safety concerns identified, the FTSE 100 listing said.

AstraZeneca said it will now seek accelerated approval in "key" markets and will present these results at a forthcoming medical meeting.

"We look forward to filing these data with regulatory authorities in key regions, while in parallel, advancing this Phase III trial towards completion," Marc Dunoyer, chief executive officer, Alexion, AstraZeneca Rare Disease, said.

Shares in AstraZeneca fell 0.5% to 14,884.00 pence each in London on Tuesday morning.

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.

Astrazeneca